1. Generics Bulletin
  2. >>Products
  3. >>Generics

Hikma Sees Field For Generic Of Advair Narrow As It Enrols Study

 
• By Aidan Fry

The challenges of developing a US generic of GlaxoSmithKline’s Advair Diskus fluticasone/salmeterol asthma blockbuster are thinning the field and improving the commercial prospects for those that succeed, Hikma believes.

Horses
High hurdles to developing a US generic of GSK's Advair Diskus inhaler are seeing several companies falling away, Hikma believes • Source: Shutterstock

Developing a generic of GlaxoSmithKline’s Advair Diskus (fluticasone/salmeterol) asthma inhaler that meets the US Food and Drug Administration’s (FDA’s) requirements is so demanding that few applicants are likely to succeed, Hikma believes. And those that do clear all the hurdles can look forward to a lucrative opportunity with limited competition, the Jordanian group’s chief executive officer, Siggi Olafsson, told investors.

Acknowledging that Hikma could “write a book” about the difficulties in developing a generic of GSK’s blockbuster brand, Olafsson insisted “that also makes it

More from Generics

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Lupin Touts FDA Approval For Generic Tolvaptan With 180-Day Exclusivity

 
• By Urtė Fultinavičiūtė

After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

More from Products